NCT04529629 is a clinical trial of surgery or drug in Complicated Adrenal Tumor Diseases, sponsored by Shanghai Jiao Tong University School of Medicine.

Who is sponsoring NCT04529629?

NCT04529629 is sponsored by Shanghai Jiao Tong University School of Medicine.

What drugs are being tested in NCT04529629?

Interventions in NCT04529629: surgery or drug.

What condition does NCT04529629 study?

NCT04529629 studies Complicated Adrenal Tumor Diseases.

Is NCT04529629 still recruiting?

NCT04529629 is currently recruiting now. Last updated 27 December 2021.

Last reviewed 2021-12-27 · How we verify

NCT04529629

Name: Drug Landscape Pharmaceutical Database
Creator: Drug Landscape
Published: 2026-01-01
License: https://creativecommons.org/licenses/by/4.0/

Precise Diagnosis, Treatment and Prognostic Evaluation of Complicated Adrenal Tumor Diseases

Recruiting now Last updated 27 December 2021

What this trial tests

trial testing surgery or drug in Complicated Adrenal Tumor Diseases in 1,000 participants. Currently enrolling.

Timeline

30 August 2021

Primary endpoint
30 August 2040

30 August 2041

Quick facts

Lead sponsor	Shanghai Jiao Tong University School of Medicine
Status	Recruiting now
Study type	OBSERVATIONAL
Enrollment	1,000
Start date	30 August 2021
Primary completion	30 August 2040
Estimated completion	30 August 2041
Sites	1 location across China

Drugs / interventions tested

surgery or drug

Conditions studied

Complicated Adrenal Tumor Diseases — all drugs for Complicated Adrenal Tumor Diseases →

Sponsor

Shanghai Jiao Tong University School of Medicine

Who can join

Adults 18 to 75, any sex, with Complicated Adrenal Tumor Diseases. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

The adrenal gland is an important organ that produces life hormones. There are many types of adrenal tumors, which tend to occur in young adults and affect the whole body. It has the dual threat: hormone secretion and tumor metastasis. At present, there are four major dilemmas in the clinical diagnosis and treatment of adrenal tumors: 1) Pulse secretion of the hormones, which are affected by many factors; and the diagnostic value of single hormone is limited; 2) Traditional imaging cannot accurately reflect the characteristics of hormone secretion. The prognosis cannot be accurately predicted; 3) The molecular characteristics of tumor cells and the microenvironment are unclear, making it difficult to implement early diagnosis and precise treatment; 4) Traditional pathology cannot determine the nature and long-term prognosis of the tumor, which makes the treatment delay, and the disease prognosis is extremely poor. It threatens the lives of patients. Starting from solving the above-mentioned key problems in the early stage, the research team has systematically established new clinical diagnostic technologies, hormone dynamic tests to accurately assess hormone secretion and segmented blood collection hormone determination technologies to accurately locate adrenal tumors; A series of important research results have been published in Science, Lancet Diabetes \& Endocrinology, Cell Research, etc To sum up, the goal of this research is improving the early diagnosis rate of complicated adrenal tumors especially in malignant tumors, developing the optimal treatment plan, avoiding unnecessary surgical treatment, improving the quality of life of patients, reducing mortality. This project will further integrate the adrenal cortex and medulla hormone mass spectrometry detection and the molecular markers of adrenal tumors through phenotypic, functional imaging, and molecular pathological evaluations, and built a sensitive drug screening platform that integrates visual drug response and molecular characteristics, thereby achieving precise diagnosis and treatment of complicated adrenal tumors.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other Shanghai Jiao Tong University School of Medicine trials

Trials by the same sponsor.

NCT07570810 — Efficacy, Safety, and Tolerability of CS0159 Combined With Semaglutide in MAFLD Patients With Obesity and T2DM · NA · not yet recruiting
NCT07528079 — Organoid-based Sensitivity-guided Chemotherapy for Advanced / Refractory Pediatric Tumors · NA · enrolling by invitation
NCT07535710 — Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Treated Cutaneous T-ce · Phase 1, PHASE2 · not yet recruiting
NCT07535762 — Aclarubicin Plus Cyclophosphamide, Vincristine, and Prednisone (CAOP) in Patients With Previously Untreated Peripheral T · Phase 2 · not yet recruiting
NCT07350057 — A Preliminary Clinical Study on the Efficacy of Cyclophosphamide and Sirolimus Combined With VIC-1911 in Preventing Graf · Phase 1 · not yet recruiting

Verify against primary sources

ClinicalTrials.gov — authoritative US registry record
WHO ICTRP — international registry index
EU Clinical Trials Register
Sponsor press releases (Google)

Data sources for this page

Trial protocol + status: ClinicalTrials.gov NCT04529629 (US National Library of Medicine, public domain)
Drug + disease cross-links: matched in real time against Drug Landscape's normalised drug + company + condition tables
Sponsor: as reported to ClinicalTrials.gov by Shanghai Jiao Tong University School of Medicine
Last refreshed: 27 December 2021

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04529629.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing